MRK | Weekly | Haru Insights

Merck (MRK) reported strong Q2 revenue of $16.61 billion, driven by Keytruda’s sustained dominance and a 57% year-over-year surge in Welireg sales, marking continued commercial strength in oncology.
The company voluntarily withdrew its Biologics License Application (BLA) for ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer due to safety concerns, including a 12.4% rate of treatment-related interstitial lung disease and two fatal cases, signaling a major setback in its ADC pipeline.

Merck’s Phase 2b success with tulisokibart in hidradenitis suppurativa represents a breakthrough in immuno-fibrosis, delivering transformative efficacy and setting the stage for a potential multi-indication blockbuster beyond oncology.
The $400 million acquisition of SPR2015, an oral KRAS G12D inhibitor, demonstrates Merck’s bold commitment to pioneering precision oncology, positioning it at the forefront of one of the most challenging and high-value targets in cancer research.
Keytruda’s sustained dominance remains a bedrock of MRK’s revenue engine, proving its enduring commercial power and ability to outpace competitors in immuno-oncology.
The 57% surge in Welireg sales reflects strong market penetration and clinical validation, reinforcing MRK’s leadership in rare oncology with a growing portfolio.
The strategic pivot toward high-value, targeted therapies like SPR2015 signals long-term vision and adaptive innovation, countering pipeline volatility with disciplined R&D execution.

Merck & Co., Inc. (MRK)[Tv]